drugset / Trial / NCT03082755

Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease

NCT03082755

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Nighttime agitation in persons with Alzheimer's disease causes patient suffering, distresses caregivers, and often results in prescriptions for harmful antipsychotics. Effective treatments are lacking because of limited knowledge of the etiology of nighttime agitation. The investigators propose a clinical trial to better elucidate whether a sleep disorder, restless legs syndrome, may be a mechanism for nighttime agitation, and if treatment with gabapentin enacarbil (Horizant®) reduces nighttime agitation, improves sleep, reduces restless legs syndrome behaviors, and reduces antipsychotic medications.

Timeline

Start
2017-07-01
Primary completion
2022-08-31
Completion
2023-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject gabapentin enacarbil Small molecule 300 mg Oral
Subject gabapentin enacarbil Small molecule 600 mg Oral

Indications